Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for XOMA Royalty Corporation’s 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) provides access to regulatory documents that reference this preferred security and its issuer. XOMA Royalty’s Form 8-K filings identify XOMAP as a class of securities registered under Section 12(b) of the Securities Exchange Act and list it alongside the company’s common stock and Series B preferred depositary shares on The Nasdaq Global Market.
Through this page, readers can review current and historical filings where XOMA Royalty reports material events, such as the completion of acquisitions of Turnstone Biologics and HilleVax, tender offers, and the use of contingent value rights in transaction structures. These documents often describe how XOMA Royalty acquires milestone and royalty rights linked to therapeutic candidates and how those transactions may affect the company’s overall financial position, which is relevant context for holders of the Series A preferred stock.
Key filings may include Form 8-K reports on completed mergers, tender offers, and financial results, as well as disclosures that list all securities registered for trading, including XOMAP. For investors focused on preferred stock, these filings can help clarify the issuer’s corporate actions, portfolio evolution, and capital structure decisions.
Stock Titan enhances this information by pairing raw SEC documents with AI-powered tools that can help explain filing sections in plain language, highlight items related to preferred securities, and surface references to dividends or other matters affecting XOMAP. Users can use this page to follow new Form 8-K submissions, periodic reports, and other SEC documents as they are made available through EDGAR.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.
Bradley Sitko, Chief Investment Officer and director of XOMA Royalty Corp (XOMAP), reported transactions dated 09/19/2025. The filing shows Sitko acquired 6,712 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock; these PSUs vest upon the common stock reaching a specified price and are scheduled to be exercisable by 05/18/2026. Following the reported PSU acquisition, Sitko beneficially owned 23,488 derivative-backed shares and 19,822 common shares by direct ownership. The report also discloses disposals of certain preferred and depositary share instruments and multiple indirect holdings through his 401(k) plan, spouse, and children.
Owen Hughes, who is listed as Chief Executive Officer and a Director of XOMA Royalty Corp, reported transactions dated 09/19/2025. The filing shows acquisition of 35,567 Performance Stock Units (PSUs) that each represent a contingent right to one share of common stock and vest upon the common stock reaching a specified price per share. After these derivative and related non‑derivative entries, Mr. Hughes is reported to beneficially own 132,714 shares on a direct basis. The filing also records a disposition of 2,000 Depository Shares of an 8.375% Series B Cumulative security. The form is signed by an attorney‑in‑fact and includes a Power of Attorney exhibit.
Thomas M. Burns, SVP, Finance & CFO of XOMA Royalty Corp (symbol: XOMAP), reported equity activity related to vested performance stock units and subsequent share sales to cover taxes. He was credited with 11,846 common shares from PSUs that vest when the stock reaches a specified price, increasing his direct common-stock holdings to 34,409 shares. Shortly thereafter he sold 4,300 shares at $35.98 and two small blocks of 15 shares each at $36.93 and $36.81, reducing his direct holdings to roughly 30,079 shares.
He also reports 6,130 shares held indirectly through a 401(k) plan and disposal of 2,000 depository shares and 2,000 series A preferred shares. The filing explains the sales were to satisfy tax withholding on PSU settlement, and the PSUs convert one-for-one into common stock with an exercisable date of 05/18/2026.
Maricel P. Montano, Chief Legal Officer and Director of XOMA Royalty Corp (XOMA), reported insider transactions dated 09/19/2025. The filing shows acquisition of 3,033 Performance Stock Units (PSUs) and 3,033 shares of Common Stock recorded as acquired with $0 price, with PSUs vesting upon the company's common stock reaching a specified price per share. After the reported transactions the filing lists 12,134 shares of common stock and 11,316 derivative units beneficially owned following the transactions. The PSUs have a stated date exercisable of 05/18/2026 per the filing. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Montano on 09/23/2025.
XOMA Royalty Corporation (XOMAP) entered into a merger with HilleVax, Inc. under an Agreement and Plan of Merger dated August 4, 2025, after a related tender offer described in an Offer to Purchase dated August 18, 2025. At the Effective Time, Merger Sub merged into HilleVax and HilleVax became a wholly owned subsidiary of XOMA, with outstanding HilleVax shares (subject to customary exceptions) cancelled and converted into the right to receive the Offer Price, comprised of a cash amount and a non-transferable Contingent Value Right (CVR).
A Contingent Value Rights Agreement dated September 17, 2025 governs potential cash payments under the CVR, with Broadridge named as rights agent and Dr. Robert Hershberg as initial representative of holders. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.
XOMA Royalty Corporation completed a merger with Turnstone Biologics Corp. under an Agreement and Plan of Merger dated June 26, 2025, effected by a merger of XOMA's wholly owned subsidiary into Turnstone under Delaware law with no stockholder vote required. At the Effective Time, each outstanding share (subject to limited exceptions) was converted into the right to receive a cash payment equal to the Cash Amount (less tax withholding) and one CVR governed by the Contingent Value Rights Agreement dated August 11, 2025. The CVR entitles holders to potential additional cash payments under specified terms, and the Offer to Purchase and Letter of Transmittal were filed as exhibits to the Schedule TO on July 23, 2025. The filing attaches the Merger Agreement, the CVR Agreement, and a press release incorporated by reference.
XOMA Royalty Corp. reporting person Maricel Perea Montano, Chief Legal Officer and director, was granted 23,450 Performance Stock Units (PSUs) on 08/12/2025. Each PSU converts to one share of XOMA common stock if a specified stock price target is met. The PSUs are shown as acquired with a $0 exercise price and are recorded as 23,450 shares beneficially owned following the award, held in a direct form.
The PSUs become eligible for issuance on 05/16/2026 subject to achieving the stated price condition. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/14/2025. No sale or cash payment is reported; this filing documents a contingent equity award tied to future stock performance.
Maricel P. Montano is identified as Chief Legal Officer and a director-level reporting person for XOMA Royalty Corp (XOMAP). The Form 3 dated 08/12/2025 indicates no securities are beneficially owned by the reporting person. The submission was signed on behalf of Montano by an attorney-in-fact, Thomas Burns, on 08/14/2025. This filing is an initial ownership statement showing the officer/director relationship but reporting no direct or indirect holdings.